Todd D Gould

List of Publications by Year
in descending order

102 papers	14,558 citations	50276 46 h-index	30087 103 g-index
106 all docs	106 docs citations	106 times ranked	15444 citing authors

#	Article	IF	Citations
1	The Endophenotype Concept in Psychiatry: Etymology and Strategic Intentions. American Journal of Psychiatry, 2003, 160, 636-645.	7.2	5,054
2	NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature, 2016, 533, 481-486.	27.8	1,246
3	Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacological Reviews, 2018, 70, 621-660.	16.0	723
4	The Role of the Extracellular Signal-Regulated Kinase Signaling Pathway in Mood Modulation. Journal of Neuroscience, 2003, 23, 7311-7316.	3.6	452
5	Toward Constructing an Endophenotype Strategy for Bipolar Disorders. Biological Psychiatry, 2006, 60, 93-105.	1.3	402
6	Mood Stabilizer Valproate Promotes ERK Pathway-Dependent Cortical Neuronal Growth and Neurogenesis. Journal of Neuroscience, 2004, 24, 6590-6599.	3.6	371
7	Glycogen Synthase Kinase-3: a Putative Molecular Target for Lithium Mimetic Drugs. Neuropsychopharmacology, 2005, 30, 1223-1237.	5.4	339
8	The Mouse Forced Swim Test. Journal of Visualized Experiments, 2011, , e3638.	0.3	316
9	AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. International Journal of Neuropsychopharmacology, 2004, 7, 387-390.	2.1	290
10	CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease. Progress in Neurobiology, 2012, 99, 1-14.	5.7	236
11	In Vivo Evidence in the Brain for Lithium Inhibition of Glycogen Synthase Kinase-3. Neuropsychopharmacology, 2004, 29, 32-38.	5.4	205
12	Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. Journal of Clinical Psychiatry, 2004, 65, 10-21.	2.2	194
13	MOLECULAR EFFECTS of lithium. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2004, 4, 259-272.	3.4	189
14	Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. Molecular Psychiatry, 2019, 24, 1040-1052.	7.9	187
15	Mood Disorder Susceptibility Gene CACNA1C Modifies Mood-Related Behaviors in Mice and Interacts with Sex to Influence Behavior in Mice and Diagnosis in Humans. Biological Psychiatry, 2010, 68, 801-810.	1.3	157
16	The Wnt Signaling Pathway in Bipolar Disorder. Neuroscientist, 2002, 8, 497-511.	3.5	155
17	Mood Stabilizers Target Cellular Plasticity and Resilience Cascades: Implications for the Development of Novel Therapeutics. Molecular Neurobiology, 2005, 32, 173-202.	4.0	139
18	Î²-Catenin Overexpression in the Mouse Brain Phenocopies Lithium-Sensitive Behaviors. Neuropsychopharmacology, 2007, 32, 2173-2183.	5.4	129

#	Article	IF	Citations
19	Convergent Mechanisms Underlying Rapid Antidepressant Action. CNS Drugs, 2018, 32, 197-227.	5.9	127
20	Antidepressant-relevant concentrations of the ketamine metabolite (2 <i>R</i> ,6 <i>R</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 T Sciences of the United States of America, 2019, 116, 5160-5169.	7.1	120
21	Signaling networks in the pathophysiology and treatment of mood disorders. Journal of Psychosomatic Research, 2002, 53, 687-697.	2.6	119
22	Targeting Glycogen Synthase Kinase-3 in the CNS: Implications for the Development of New Treatments for Mood Disorders. Current Drug Targets, 2006, 7, 1399-1409.	2.1	118
23	The behavioral actions of lithium in rodent models: Leads to develop novel therapeutics. Neuroscience and Biobehavioral Reviews, 2007, 31, 932-962.	6.1	115
24	Strain Differences in Lithium Attenuation of d-Amphetamine-Induced Hyperlocomotion: A Mouse Model for the Genetics of Clinical Response to Lithium. Neuropsychopharmacology, 2007, 32, 1321-1333.	5.4	113
25	(<i>2R,6R</i>)-hydroxynorketamine exerts mGlu ₂ receptor-dependent antidepressant actions. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6441-6450.	7.1	112
26	Animal models of bipolar disorder and mood stabilizer efficacy: A critical need for improvement. Neuroscience and Biobehavioral Reviews, 2007, 31, 825-831.	6.1	109
27	Performance on a Virtual Reality Spatial Memory Navigation Task in Depressed Patients. American Journal of Psychiatry, 2007, 164, 516-519.	7.2	98
28	Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test. Neuropharmacology, 2008, 54, 577-587.	4.1	98
29	Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants. Annual Review of Pharmacology and Toxicology, 2019, 59, 213-236.	9.4	98
30	Allergic rhinitis induces anxiety-like behavior and altered social interaction in rodents. Brain, Behavior, and Immunity, 2009, 23, 784-793.	4.1	96
31	The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/Glycine_B-Site Inhibition. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 76-85.	2.5	96
32	Molecular actions and clinical pharmacogenetics of lithium therapy. Pharmacology Biochemistry and Behavior, 2014, 123, 3-16.	2.9	95
33	Lithium's Antisuicidal Efficacy: Elucidation of Neurobiological Targets Using Endophenotype Strategies. Annual Review of Pharmacology and Toxicology, 2009, 49, 175-198.	9.4	94
34	Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters. Journal of Pharmacology and Experimental Therapeutics, 2016, 359, 159-170.	2.5	89
35	A Negative Allosteric Modulator for Î±5 Subunit-Containing GABA Receptors Exerts a Rapid and Persistent Antidepressant-Like Action without the Side Effects of the NMDA Receptor Antagonist Ketamine in Mice. ENeuro, 2017, 4, ENEURO.0285-16.2017.	1.9	88
36	Post-mortem Interval Effects on the Phosphorylation of Signaling Proteins. Neuropsychopharmacology, 2003, 28, 1017-1025.	5.4	83

#	ARTICLE	IF	CITATIONS
37	Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects. Psychopharmacology, 2018, 235, 3017-3030.	3.1	81
38	Motor neuron disease, TDP-43 pathology, and memory deficits in mice expressing ALSâ€“FTD-linked <i>UBQLN2</i> mutations. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7580-E7589.	7.1	77
39	Generation and behavioral characterization of Î²-catenin forebrain-specific conditional knock-out mice. Behavioural Brain Research, 2008, 189, 117-125.	2.2	76
40	Altered performance on an ocular fixation task in attention-deficit/hyperactivity disorder. Biological Psychiatry, 2001, 50, 633-635.	1.3	68
41	Antidepressant-like responses to lithium in genetically diverse mouse strains. Genes, Brain and Behavior, 2011, 10, 434-443.	2.2	66
42	Mechanisms of ketamine and its metabolites as antidepressants. Biochemical Pharmacology, 2022, 197, 114892.	4.4	66
43	Synthesis and <i>N</i>-Methyl-<scp>d</scp>-aspartate (NMDA) Receptor Activity of Ketamine Metabolites. Organic Letters, 2017, 19, 4572-4575.	4.6	64
44	(<i>R</i>)â€Ketamine exerts antidepressant actions partly via conversion to (<i>2R,6R</i>)â€hydroxynorketamine, while causing adverse effects at subâ€anaesthetic doses. British Journal of Pharmacology, 2019, 176, 2573-2592.	5.4	61
45	Mood stabilizer psychopharmacology. Clinical Neuroscience Research, 2002, 2, 193-212.	0.8	59
46	Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications. Pharmacological Reviews, 2021, 73, 763-791.	16.0	54
47	Dopamine and Stress System Modulation of Sex Differences in Decision Making. Neuropsychopharmacology, 2018, 43, 313-324.	5.4	53
48	The prodrug DHED selectively delivers 17Î²-estradiol to the brain for treating estrogen-responsive disorders. Science Translational Medicine, 2015, 7, 297ra113.	12.4	51
49	DARPP-32: A molecular switch at the nexus of reward pathway plasticity. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 253-254.	7.1	50
50	The Molecular Medicine Revolution and Psychiatry: Bridging the Gap Between Basic Neuroscience Research and Clinical Psychiatry. Journal of Clinical Psychiatry, 2004, 65, 598-604.	2.2	48
51	Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. Neuropsychopharmacology, 2020, 45, 1398-1404.	5.4	47
52	Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice. Pharmacological Research, 2003, 48, 49-53.	7.1	46
53	Group II metabotropic glutamate receptor blockade promotes stress resilience in mice. Neuropsychopharmacology, 2019, 44, 1788-1796.	5.4	45
54	(2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism. Neuropsychopharmacology, 2020, 45, 426-436.	5.4	42

#	Article	IF	Citations
55	A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression. International Journal of Neuropsychopharmacology, 2020, 23, 417-425.	2.1	42
56	Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (<i>2R,6R</i>)-hydroxynorketamine. Journal of Psychopharmacology, 2019, 33, 12-24.	4.0	41
57	Ketamine and the Future of Rapid-Acting Antidepressants. Annual Review of Clinical Psychology, 2021, 17, 207-231.	12.3	40
58	Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications. Expert Opinion on Therapeutic Targets, 2006, 10, 377-392.	3.4	34
59	Shock-induced aggression in mice is modified by lithium. Pharmacology Biochemistry and Behavior, 2010, 94, 380-386.	2.9	33
60	Intracellular Signaling Pathways Involved in (S)- and (R)-Ketamine Antidepressant Actions. Biological Psychiatry, 2018, 83, 2-4.	1.3	33
61	Ubiquilin-1 Overexpression Increases the Lifespan and Delays Accumulation of Huntingtin Aggregates in the R6/2 Mouse Model of Huntington's Disease. PLoS ONE, 2014, 9, e87513.	2.5	33
62	Advances in multidisciplinary and cross-species approaches to examine the neurobiology of psychiatric disorders. European Neuropsychopharmacology, 2011, 21, 532-544.	0.7	31
63	Lithium, but not Valproate, Reduces Impulsive Choice in the Delay-Discounting Task in Mice. Neuropsychopharmacology, 2013, 38, 1937-1944.	5.4	31
64	Immune status influences fear and anxiety responses in mice after acute stress exposure. Brain, Behavior, and Immunity, 2014, 38, 192-201.	4.1	31
65	Zanos et al. reply. Nature, 2017, 546, E4-E5.	27.8	29
66	Reduced levels of <i><scp>C</scp>acna1c</i> attenuate mesolimbic dopamine system function. Genes, Brain and Behavior, 2017, 16, 495-505.	2.2	28
67	Decreased Nucleus Accumbens Expression of Psychiatric Disorder Risk Gene Cacna1c Promotes Susceptibility to Social Stress. International Journal of Neuropsychopharmacology, 2017, 20, 428-433.	2.1	28
68	Sexâ€dependent modulation of ageâ€related cognitive decline by the Lâ€type calcium channel gene <i>Cacna1c</i> (Ca_v1.2). European Journal of Neuroscience, 2015, 42, 2499-2507.	2.6	26
69	Reply to: Antidepressant Actions of Ketamine Versus Hydroxynorketamine. Biological Psychiatry, 2017, 81, e69-e71.	1.3	22
70	Ketamine Mechanism of Action: Separating the Wheat from the Chaff. Neuropsychopharmacology, 2017, 42, 368-369.	5.4	21
71	Isoflurane but Not Halothane Prevents and Reverses Helpless Behavior: A Role for EEG Burst Suppression?. International Journal of Neuropsychopharmacology, 2018, 21, 777-785.	2.1	21
72	Psychological stress enhances tumor growth and diminishes radiation response in preclinical model of lung cancer. Radiotherapy and Oncology, 2020, 146, 126-135.	0.6	21

#	Article	IF	Citations
73	Chronic lithium treatment rectifies maladaptive dopamine release in the nucleus accumbens. Journal of Neurochemistry, 2016, 139, 576-585.	3.9	20
74	Alpha2B-Adrenergic Receptor Overexpression in the Brain Potentiate Air Pollution-induced Behavior and Blood Pressure Changes. Toxicological Sciences, 2019, 169, 95-107.	3.1	20
75	Sex-Specific Involvement of Estrogen Receptors in Behavioral Responses to Stress and Psychomotor Activation. Frontiers in Psychiatry, 2019, 10, 81.	2.6	17
76	Affect-Related Behaviors in Mice Selectively Bred for High and Low Voluntary Alcohol Consumption. Behavior Genetics, 2012, 42, 313-322.	2.1	16
77	A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801. Neurotoxicology and Teratology, 2021, 87, 106993.	2.4	15
78	Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2<i>,</i>6)- and (5<i>R</i>)-Methyl-(2<i>R,</i>6<i>R</i>)-hydroxynorketamines. ACS Chemical Neuroscience, 2022, 13, 510-523.	3.5	15
79	Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search. Molecular Psychiatry, 2022, 27, 4144-4156.	7.9	15
80	Treatment of depression with ketamine does not change plasma levels of brain-derived neurotrophic factor or vascular endothelial growth factor. Journal of Affective Disorders, 2021, 280, 136-139.	4.1	14
81	Negative Allosteric Modulation of Gamma-Aminobutyric Acid A Receptors at Î±5 Subunitâ€“Containing Benzodiazepine Sites Reverses Stress-Induced Anhedonia and Weakened Synaptic Function in Mice. Biological Psychiatry, 2022, 92, 216-226.	1.3	14
82	Differential antidepressant-like response to lithium treatment between mouse strains: effects of sex, maternal care, and mixed genetic background. Psychopharmacology, 2013, 228, 411-418.	3.1	13
83	Ketamine metabolite (2R,6R)-hydroxynorketamine reverses behavioral despair produced by adolescent trauma. Pharmacology Biochemistry and Behavior, 2020, 196, 172973.	2.9	13
84	Cigarette smoke and nicotine effects on brain proinflammatory responses and behavioral and motor function in HIV-1 transgenic rats. Journal of NeuroVirology, 2018, 24, 246-253.	2.1	12
85	Sex-dependent metabolism of ketamine and (<i>2R,6R</i>)-hydroxynorketamine in mice and humans. Journal of Psychopharmacology, 2022, 36, 170-182.	4.0	12
86	Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis. Molecular Psychiatry, 2022, 27, 3658-3669.	7.9	12
87	Neurotrophic signaling cascades are major long-term targets for lithium: clinical implications. Clinical Neuroscience Research, 2004, 4, 137-153.	0.8	10
88	(R,S)-ketamine and (2R,6R)-hydroxynorketamine differentially affect memory as a function of dosing frequency. Translational Psychiatry, 2021, 11, 583.	4.8	10
89	Antidepressant Effects and Mechanisms of Group II mGlu Receptor-Specific Negative Allosteric Modulators. Neuron, 2020, 105, 1-3.	8.1	9
90	GSK-3 and neurotrophic signaling: novel targets underlying the pathophysiology and treatment of mood disorders?. Drug Discovery Today Disease Mechanisms, 2004, 1, 419-428.	0.8	8

#	Article	IF	Citations
91	Effect of lithium on behavioral disinhibition induced by electrolytic lesion of the median raphe nucleus. Psychopharmacology, 2015, 232, 1441-1450.	3.1	8
92	Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration. Translational Psychiatry, 2022, 12, 179.	4.8	8
93	(2R,6R)-hydroxynorketamine rapidly potentiates optically-evoked Schaffer collateral synaptic activity. Neuropharmacology, 2022, 214, 109153.	4.1	8
94	Classical conditioning of antidepressant placebo effects in mice. Psychopharmacology, 2020, 237, 93-102.	3.1	7
95	F102. Human Experimenter Sex Modulates Mouse Behavioral Responses to Stress and to the Antidepressant Ketamine. Biological Psychiatry, 2018, 83, S277.	1.3	6
96	Rare variants implicate NMDA receptor signaling and cerebellar gene networks in risk for bipolar disorder. Molecular Psychiatry, 2022, 27, 3842-3856.	7.9	5
97	Differential Lithium Efficacy in Reducing Suicidal Behaviors Compared With Suicidal Thoughts. American Journal of Psychiatry, 2012, 169, 98-99.	7.2	3
98	7B2 chaperone knockout in APP model mice results in reduced plaque burden. Scientific Reports, 2018, 8, 9813.	3.3	3
99	Effects of environmental stress following myocardial infarction on behavioral measures and heart failure progression: The influence of isolated and group housing conditions. Physiology and Behavior, 2015, 152, 168-174.	2.1	2
100	Irving I. Gottesman (1930â€"2016): the multifactorial threshold model of complex phenotypes mediated by endophenotype strategies. Genes, Brain and Behavior, 2016, 15, 775-776.	2.2	2
101	Targeting Neurotrophic Signal Transduction Pathways in the Treatment of Mood Disorders. Current Signal Transduction Therapy, 2007, 2, 101-110.	0.5	2
102	Going longitudinal in biological psychiatric research: All things considered. Neuroscience Research, 2016, 102, 1-3.	1.9	1